- Home
- INFY vs REGN Comparison
INFY vs REGN Comparison
Compare INFY & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INFY | REGN |
|---|---|---|
| Founded | 1981 | 1988 |
| Country | India | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.7B | 79.4B |
| IPO Year | 1999 | 1991 |
Fundamental Metrics
Financial Performance| Metric | INFY | REGN |
|---|---|---|
| Price | $14.65 | $798.79 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 6 | 23 |
| Target Price | $17.60 | ★ $812.57 |
| AVG Volume (30 Days) | ★ 14.1M | 885.1K |
| Earning Date | 01-14-2026 | 01-30-2026 |
| Dividend Yield | ★ 2.98% | 0.47% |
| EPS Growth | N/A | ★ 8.19 |
| EPS | 0.78 | ★ 41.48 |
| Revenue | ★ $19,847,000,000.00 | $14,342,900,000.00 |
| Revenue This Year | $2.49 | $10.39 |
| Revenue Next Year | $6.53 | $9.73 |
| P/E Ratio | ★ $19.03 | $19.36 |
| Revenue Growth | ★ 3.85 | 0.99 |
| 52 Week Low | $14.19 | $476.49 |
| 52 Week High | $30.00 | $821.11 |
Technical Indicators
Market Signals| Indicator | INFY | REGN |
|---|---|---|
| Relative Strength Index (RSI) | 28.94 | 61.57 |
| Support Level | $14.19 | $745.07 |
| Resistance Level | $16.74 | $790.00 |
| Average True Range (ATR) | 0.55 | 24.14 |
| MACD | -0.33 | 3.45 |
| Stochastic Oscillator | 11.70 | 95.97 |
Price Performance
Historical ComparisonAbout INFY Infosys Limited
Infosys is an IT services provider based in Bengaluru, India, with offices in more than 50 countries. The company leverages its offshore outsourcing model to serve clients across different industries, such as financial services and manufacturing. Infosys' IT services offerings include consulting, digital transformation, and business process outsourcing.
About REGN Regeneron Pharmaceuticals Inc.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).